Values are mean + SEM.
(n=5 per group).
aP<0.0001 and abP<0.05 significantly higher from the diabetic group treated with
levcromakalim.
D: diabetic group
LevD : potassium channel activated diabetic group
LevDG : potassium channel activated diabetic group treated with glibenclamide
LevDM: potassium channel activated diabetic group treated with metformin
LevDI20/40 : potassium channel activated diabetic group treated with insulin
Figure 2: The effect of levcromakalim treatment on the creatinine clearance of streptozotocin-induced rats treated with glibenclamide, metformin and insulin.